In response to: “Innovative cellular therapies for autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committee” by Greco et al.
Year: 2024
Type: article
Abstract: We would like to highlight four points regarding recent EBMT recommendations for the use of chimeric antigen receptor (CAR) T cells in autoimmune diseases.1 First, the recommendations are based on conventional, integrating vector-based CAR-Ts, which require lymphodepletion chemotherapy, inpatient administration and prolonged post-infusion monitoring. In phase 1/2 trials in generalized myasthenia gravis, mRNA CAR-Ts were administered outpatient, without lymphodepletion, and resulted in no cytokine release syndrome or neurotoxicity.
Source: EClinicalMedicine
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $5,000
Funders: Amgen, Myasthenia Gravis Foundation of America, AstraZeneca, Merck, Sanofi, Muscular Dystrophy Association, Patient-Centered Outcomes Research Institute, Alexion Pharmaceuticals, Regeneron Pharmaceuticals, Valerion Therapeutics, Amicus Therapeutics, Audentes Therapeutics, Argenx, Horizon Therapeutics, Astellas Pharma, Grifols, National Institutes of Health, Centers for Disease Control and Prevention, Novartis Pharma, Spark Therapeutics, National Institute of Allergy and Infectious Diseases, UCB Pharma, Cartesian Therapeutics
OpenAlex ID: W4404603074